HEK293 Cell Line for rAAV Manufacturing - Summary - MDSpire

HEK293 Cell Line for rAAV Manufacturing

New study reports two-fold improvement in full-to-empty rAAV ratio versus commercial HEK293 line

  • March 4, 2026

  • 3 min

Share

Objective:

To present the development and characterization of the NBX1P01 clonal HEK293 cell line for improved recombinant adeno-associated virus (rAAV) production.

Key Findings:
  • NBX1P01 produced a two-fold higher full-to-empty rAAV capsid ratio compared to a leading commercial HEK293 cell line.
  • The clone remained genomically stable over 55 population doubling levels with lower genetic heterogeneity.
  • Long-read sequencing confirmed over 70% intact rAAV genomes with minimal contaminating DNA.
  • Consistent performance was demonstrated across production volumes from 10 mL to 1.5 L and supported multiple rAAV serotypes.
Interpretation:

The NBX1P01 cell line represents a significant advancement in rAAV manufacturing, addressing key challenges in scalability and product quality for gene therapy applications.

Limitations:
  • The study does not address long-term performance beyond 55 population doublings.
  • Further validation in diverse production settings may be required.
Conclusion:

NBX1P01 offers a reliable and consistent platform for high-quality rAAV production, essential for advancing gene therapy accessibility.

Original Source(s)

HEK293 Cell Line for rAAV Manufacturing

  • March 4, 2026

Related Content

Low-Dose PFAS Exposure Alters Cellular Metabolism 

Cell culture model reveals lipid remodeling and oxidative stress following prolonged PFAS exposure 

  • March 24, 2026

  • 2 min
Mining the Literature for Bioprocess Gains

Automated text extraction connects culture conditions, purification steps, and productivity metrics

  • March 10, 2026

  • 2 min
GlycoRNA Comes into Focus with Mass Spectrometry Blueprint

New review maps analytical workflows to decode a surprising class of sugar-coated RNA

  • March 30, 2026

  • 2 min